Westpac Banking Corp increased its stake in shares of Boston Scientific Co. (NYSE:BSX) by 114.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 217,697 shares of the medical equipment provider’s stock after acquiring an additional 116,417 shares during the quarter. Westpac Banking Corp’s holdings in Boston Scientific were worth $9,357,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the stock. Investors Research Corp increased its stake in Boston Scientific by 333.3% in the second quarter. Investors Research Corp now owns 650 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 500 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in Boston Scientific by 60.0% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 800 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 300 shares during the period. Essex Savings Bank acquired a new position in Boston Scientific in the first quarter valued at $31,000. Westside Investment Management Inc. acquired a new position in Boston Scientific in the second quarter valued at $31,000. Finally, NEXT Financial Group Inc increased its stake in Boston Scientific by 222.3% in the second quarter. NEXT Financial Group Inc now owns 780 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 538 shares during the period. Hedge funds and other institutional investors own 90.60% of the company’s stock.

A number of research analysts have commented on the stock. Wells Fargo & Co lifted their price objective on shares of Boston Scientific from $42.00 to $45.00 and gave the company an “outperform” rating in a research note on Tuesday, June 18th. Leerink Swann set a $50.00 price objective on shares of Boston Scientific and gave the company a “buy” rating in a research note on Wednesday, July 31st. Raymond James lifted their price objective on shares of Boston Scientific from $48.00 to $50.00 and gave the company a “strong-buy” rating in a research note on Thursday, July 25th. Needham & Company LLC set a $46.00 price objective on shares of Boston Scientific and gave the company a “buy” rating in a research note on Wednesday, July 24th. Finally, Jefferies Financial Group lifted their price objective on shares of Boston Scientific from $44.00 to $48.00 and gave the company a “positive” rating in a research note on Thursday, June 27th. Four investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $44.91.

In related news, SVP Jodi Euerle Eddy sold 7,803 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $38.42, for a total transaction of $299,791.26. Following the sale, the senior vice president now owns 88,978 shares of the company’s stock, valued at $3,418,534.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 1,906 shares of the business’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $43.00, for a total transaction of $81,958.00. Following the sale, the executive vice president now directly owns 226,835 shares in the company, valued at approximately $9,753,905. The disclosure for this sale can be found here. In the last ninety days, insiders sold 63,289 shares of company stock worth $2,611,790. Insiders own 0.66% of the company’s stock.

Shares of NYSE:BSX traded up $0.25 during midday trading on Thursday, hitting $41.68. The stock had a trading volume of 32,074 shares, compared to its average volume of 5,758,131. The stock has a market cap of $57.65 billion, a P/E ratio of 28.44, a PEG ratio of 2.54 and a beta of 0.80. The company’s 50 day moving average price is $42.52. The company has a quick ratio of 1.04, a current ratio of 1.31 and a debt-to-equity ratio of 0.81. Boston Scientific Co. has a 1 year low of $31.56 and a 1 year high of $43.66.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.01. The business had revenue of $2.63 billion for the quarter, compared to the consensus estimate of $2.64 billion. Boston Scientific had a net margin of 13.85% and a return on equity of 23.29%. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.41 earnings per share. Equities analysts forecast that Boston Scientific Co. will post 1.56 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

See Also: What is the Russell 2000 Index?

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.